In vitro molecular diagnostics (IVD) play an important role in effective disease management. The need for IVD assays continues to grow as increasingly sophisticated bioinformatics tools enable the identification of novel biomarkers associated with disease. With these advances, the need for accurate assays to measure these biomarkers increases. To build a quality IVD assay, it is imperative to have quality reagents.
The Selexis SUREtechnology Platform™ and the Selexis’ world-class expert services allow for the generation of stable cell lines expressing high levels of high quality diagnostic reagents such as monoclonal antibodies or growth factors for immunoassays or companion diagnostics. The Selexis SUREtechnology Platform™ generates stable and high performing mammalian cell lines generating g/L quantities of diagnostic reagent proteins in as little as 3 months from the time of transfection. These cell lines are stable for >60 generations which ensures consistent production, quantity and quality of the reagent proteins.
With the discovery of novel biomarkers, developing the best assay may still require identifying the best reagents. Selexis SUREvariant screening™ is a cost effective way to improve the outcomes from screening reagents for the optimal properties in diagnostic assays.
Diagnostics generated using the Selexis SURE Cell line development™ technology have the advantages of:
- High expression
- Reduces the size and number of production runs
- Expression stable
- Reduces the risk of product variability between lots.
- Selexis SUREvariant screening
- Technology that drives screening campaigns assessing reagents for optimal activity
